Annual revenue rose from KRW 110.2 billion in 2022 to KRW 112.9 billion in 2023, up 2.5%, before falling 7.9% to KRW 104 billion in 2024 and 1.2% to KRW 102.7 billion in 2025, a two-year decline from 2024 through 2025. Within 2022 to 2025, 2023 was the largest year and 2025 the smallest.
Operating profit fell from KRW 17 billion in 2022 to KRW 10.1 billion in 2023, down 40.6%, dipped to KRW 8.85 billion in 2024, down 12.1%, and recovered slightly to KRW 9.03 billion in 2025, up 2.0%.
The operating margin dropped from 15.4% in 2022 to 8.9% in 2023 and then stayed in the 8% range, at 8.5% in 2024 and 8.8% in 2025. In 2023 revenue grew 2.5% while operating profit fell 40.6%, so the margin decline was concentrated in that year.
Net profit attributable to controlling shareholders fell from KRW 14.4 billion in 2022 to KRW 9.19 billion in 2023, down 36.1%, recovered to KRW 10.1 billion in 2024, up 10.4%, and then declined to KRW 6.78 billion in 2025, down 33.2%.
The net profit figures including non-controlling interests are, for each year from 2022 to 2025, the same amounts as net profit attributable to controlling shareholders.
At the end of 2025, total equity was KRW 92.1 billion and total liabilities were KRW 29.9 billion, while operating cash flow was KRW 7.35 billion in 2022, KRW 15 billion in 2023, KRW 3.68 billion in 2024 and KRW 11.6 billion in 2025, with wide swings between years.
Quarterly revenue rose from KRW 24.4 billion in the third quarter of 2025 to KRW 27.9 billion in the fourth quarter, up 14.5%, dipped 2.0% to KRW 27.3 billion in the first quarter of 2026, and then grew to KRW 29.9 billion in the second quarter, up 9.4%, and KRW 42.8 billion in the third quarter, up 43.3%.
Operating profit bottomed at KRW 2.16 billion in the fourth quarter of 2025 and then rose to KRW 2.74 billion, KRW 3.5 billion and KRW 6.42 billion over the next three quarters.
Over the same period, net profit attributable to controlling shareholders peaked at KRW 3.98 billion in the first quarter of 2026 and then fell to KRW 3.58 billion and KRW 2.16 billion.
Third-quarter operating profit grew 190.6% year on year against 8.0% growth in net profit, a wide gap between the operating and net profit lines.
The company said in August 2026 that a KRW 19.3 billion medical equipment supply contract in Turkey would be reflected from the third quarter, a timing that coincides with the third-quarter revenue increase.
The four quarters from Q4 2025 to Q3 2026 total KRW 12.4 billion in net profit attributable to controlling shareholders, below the KRW 14.4 billion recorded for 2022 alone.